• Explore /
  • Poster
  • / Double-blind, randomized phase III study to compare the efficacy and safety of CT-P6, trastuzumab biosimilar candidate versus trastuzumab as neoadjuvant treatment in HER2 positive early breast cancer (EBC).

Double-blind, randomized phase III study to compare the efficacy and safety of CT-P6, trastuzumab biosimilar candidate versus trastuzumab as neoadjuvant treatment in HER2 positive early breast cancer (EBC).

Abstract Poster

Authors

null

Justin Stebbing

Imperial College Healthcare NHS Trust, London, United Kingdom

Justin Stebbing , Yauheni Valerievich Baranau , Valery Baryash , Alexey Manikhas , Vladimir Moiseyenko , Giorgi Dzagnidze , Edvard Javrid , Dmytro Boliukh , Daniil Stroyakovskiy , Joanna Pikiel , Alexandru E. Eniu , Dmitry Komov , Zakaria Zautashvili , Gabriela Morar-Bolba , Rubi Khaw Li , Igor Lifirenko , Andriy V. Rusyn , Sang Joon Lee , Sung Young Lee , Francisco J. Esteva

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Neoadjuvant Therapy

Clinical Trial Registration Number

NCT02162667

Citation

J Clin Oncol 35, 2017 (suppl; abstr 510)

DOI

10.1200/JCO.2017.35.15_suppl.510

Abstract #

510

Poster Bd #

110

Abstract Disclosures

Similar Posters

First Author: Xavier B. Pivot

First Author: Christian Jackisch

First Author: Atara Isaiah Ntekim

First Author: Hans-Christian Kolberg